ABSTRACT
Developing and deploying new diagnostic tests is difficult, but the need to do so in response to a rapidly emerging pandemic such as COVID-19 is crucially important for an effective response. In the early stages of a pandemic, laboratories play a key role in helping health care providers and public health authorities detect active infection, a task most commonly achieved using nucleic acid-based assays. While the landscape of diagnostics is rapidly evolving, polymerase chain reaction (PCR) remains the gold-standard of nucleic acid-based diagnostic assays, in part due to its reliability, flexibility, and wide deployment. To address a critical local shortage of testing capacity persisting during the COVID-19 outbreak, our hospital set up a molecular based laboratory developed test (LDT) to accurately and safely diagnose SARS-CoV-2. We describe here the process of developing an emergency-use LDT, in the hope that our experience will be useful to other laboratories in future outbreaks and will help to lower barriers to fast and accurate diagnostic testing in crisis conditions.
Competing Interest Statement
Pardis Sabeti is a founder and shareholder of Sherlock Biosciences, and is both on the Board and serves as shareholder of the Danaher Corporation. Jacob Lemieux is a consultant for Sherlock Biosciences. Melis N. Anahtar is a co-founder, equity holder, and consultant for Day Zero Diagnostics. Pardis Sabeti, Edward T. Ryan, and Sarah E. Turbett have received CDC funding for this work and other COVID-related work.
Funding Statement
Parts of this work were supported through a grant from the Centers for Disease Control and Prevention (U01 CK000490), as well as a grant from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID 2U19AI110818-06).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This paper documents work in the CLIA certified MGH microbiology lab performed on clinical or clinical excess samples, and is covered under MGH's diagnostics and sequencing protocol for respiratory pathogens: IRB 2019P003305.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All of the data is either shared in the manuscript or can be made available on request.
